VEGFA and hepatocellular carcinoma: Previous meta-analyses have also demonstrated that anti-PD-1/PD-L1 antibodies in combination with anti-VEGFR/VEGFA prolonged survival time and improved treatment efficacy in HCC patients [59,60].